Oneness Biotech Advances SNS851 Obesity Drug Candidate to Multiple-Ascending Dose Phase I Trial
Oneness Biotech (TW: 4743) has completed the single-ascending dose (SAD) portion of its Phase I clinical trial of SNS851, an
Read MoreOneness Biotech (TW: 4743) has completed the single-ascending dose (SAD) portion of its Phase I clinical trial of SNS851, an
Read MoreTaiwan’s Caliway Biopharmaceuticals (TW: 6919) has reported positive final results from a Phase II trial of CBL-514D, demonstrating statistically significant
Read MoreTaiwan’s Merry Life Biomedical has advanced its locally-developed oral drug candidate TML-6 into a global Phase II clinical trial for
Read MorePresident Lai Ching-te lauded Taiwan’s efforts in cancer research and treatment in a video address marking the 20th anniversary of
Read MoreAnxo Pharmaceutical (TW: 6677), a developer of drug delivery technologies, announced in a press release on the 14th of September
Read MoreThe 3rd Healthy Ageing Tech Show opened on August 7 at Taipei World Trade Center Hall 1 under the theme
Read More